Important Safety Information Do not use AOD-9604 if you: Have a known allergy to growth hormone fragments or any component of the formulation Have been diagnosed with active cancer or have a history of malignancy (use only under medical supervision) Are pregnant or breastfeeding (safety data is lacking) Have severe uncontrolled diabetes or metabolic disorders without medical supervision Common side effects may include: Injection site reactions, mild headaches, temporary fatigue, or slight dizziness during initial use
Ismail, N., Becker, B., Strzelczyk, P
in Value in Health modeled lifetime costs and quality-adjusted life years (QALYs) for three strategies: Indefinite semaglutide treatment 1-year treatment followed by discontinuation No pharmacotherapy (behavioral intervention only) For patients who lost 15%+ body weight on treatment, indefinite continuation was cost-effective at a willingness-to-pay threshold of $100,000 per QALY, primarily due to reduced diabetes and cardiovascular disease costs
These studies indicated that VP1-001 also improved cataracts in human lenses ex vivo
the mailing address if a return shipment is required
Hewitt S, Humerfelt S, Sovik TT, et al